Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 4Terminated 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Uveal Melanoma 1Neoplasm Metastasis 1Melanoma 1

Interventions

pembrolizumab 58Ipilimumab 53Cyclophosphamide 53Nivolumab 45aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 19dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11spartalizumab 10Filgrastim 10Dacarbazine 10cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × fotemustine × Dermatologic × Clear all
NCT00560118 2025-02-14

MGFOT1

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2 Terminated
12 enrolled
Dermatologic

Melanoma

NCT00110123 2012-09-24

Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Terminated
171 enrolled
Dermatologic

Uveal Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡